ReviewFrontiers in oncology2013
Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF.
Review in Frontiers in oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 65 citations in OpenAlex.
- Pan-cancer prevalence of microsatellite instability and Lynch syndrome in India.Familial cancer · 2026Article
- Biology and evolving management of resectable dMMR/MSI-H cancers: current status and future perspectives.Cancer immunology, immunotherapy : CII · 2025Review
- Association of MDM2 Overexpression in Ameloblastomas withInternational journal of molecular sciences · 2024Article
- Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice.Journal for immunotherapy of cancer · 2022Article
- Implication of gut microbiome in immunotherapy for colorectal cancer.World journal of gastrointestinal oncology · 2022Review
- Review
- Review
- Prevalence of theJournal of investigative medicine : the official publication of the American Federation for Clinical Research · 2020Article
- BRAF-V600E and microsatellite instability prediction through CA-19-9/CEA ratio in patients with colorectal cancer.Journal of gastrointestinal oncology · 2020Article
- DRP1 Promotes BRAFFrontiers in oncology · 2020Article
- Prognostic Relevance of SFRP1 Gene Promoter Methylation in Colorectal CarcinomaAsian Pacific journal of cancer prevention : APJCP · 2019Article
- Mucinous colorectal adenocarcinoma: clinical pathology and treatment options.Cancer communications (London, England) · 2019Review
- The role of autophagy in the treatment of BRAF mutant colorectal carcinomas differs based on microsatellite instability status.PloS one · 2018Article
- Observational
- KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma.Medical oncology (Northwood, London, England) · 2017Review
- Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells.Cancer cell international · 2017Article
- BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-Type BRAF-Expressing Cancer Independent of the Microsatellite Instability Status.Journal of Korean medical science · 2017Article
- BRAFV600E-dependent Mcl-1 stabilization leads to everolimus resistance in colon cancer cells.Oncotarget · 2016Article
- A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC.Nature communications · 2016Article
- Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy.World journal of gastroenterology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Different genetic aberrations of BRAF have been reported in various malignancies. BRAF is member of the RAS/RAF/MEK/ERK pathway and constitutive activity of this pathway can lead to increased cellular growth, invasion, and metastasis. The most common activating BRAF mutation in colorectal cancer is the V600E mutation, which is present in 5-15% of all tumors, and up to 80% of tumors with high microsatellite instability (MSI) harbor this mutation. BRAF mutation is associated with proximal location, higher age, female gender, MSI-H, high grade, and mucinous histology, and is a marker of poor prognosis in colorectal cancer. The role of BRAF mutation as a predictive marker in respect of EGFR targeted treatments is controversial. BRAF V600 selective inhibitors have been approved for the treatment of V600 mutation positive metastatic melanoma, but the response rates in colorectal cancer are poor. This might be due to innate resistance mechanisms of colorectal cancers against the treatment solely targeting BRAF. To overcome resistance the combination of treatments, simultaneous inhibition of BRAF and MEK or PI3K/mTOR, might emerge as a successful therapeutic concept.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.